$599

Daprodustat US approval in question after vada CRL; Akebia post-CRL investor call highlights

Following the vadadustat CRL issued on March 30, 2022, Akebia hosted a call with investors to discuss the steps forward. Below FENIX provides highlights and insights from the call, including readthrough to GSK’s daprodustat.

This content is for Read Less members only.
Register
Already a member? Log in here